Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Graduate Institute of Clinical Medicine, Medical College, National Taiwan University, Taipei, Taiwan.
Aging (Albany NY). 2022 Aug 5;14(15):6111-6127. doi: 10.18632/aging.204202.
Data comparing the neurocognitive trajectory between low and intermediate-high risk patients following transcatheter aortic valve replacement (TAVR) is never reported.
To report serial neurocognitive changes up to 1 year post-TAVR in low and intermediate-high risk groups as well as overall cohort.
Prospective neurological assessments (NIHSS and Barthel Index), global cognitive tests (MMSE and Alzheimer Disease Assessment Scale-Cognitive Subtest, ADAS-cog) and executive performances (Color Trail Test A and B and verbal fluency), were applied at baseline, 3 months and 1 year post-TAVR.
In overall cohort, persistent improvement to 1 year in MMSE, ADAS-cog, Color Trail Test A and B was found. According to the STS score, the study cohort was divided into low (<4%, = 81) and intermediate-high (≧4%, = 75) risk groups. The baseline neurologic and cognitive performance was significantly worse in intermediate-high risk group. Slight improvement on general neurological functions (Barthel index and proportion of NIHSS>0 patients) at 1 year could be observed only in intermediate-high risk group. In global cognitive assessments, improvement in MMSE and ADAS-cog at 1 year was found in both groups, but the proportion of cognitive improvement was more obvious in intermediate-high risk group. In Color Trail Tests and verbal fluency, significant and persistent improvement up to 1 year could be observed only in low risk group.
TAVR was associated with persistent improvement in global cognitive function, as well as in attention and psychomotor processing speed, up to 1 year in overall cohort. However, improvement in tests for executive functions can only be seen in low risk group.
从未有研究报告过经导管主动脉瓣置换术(TAVR)后低危和中高危患者之间的神经认知轨迹数据。
报告 TAVR 后 1 年内低危和中高危组以及总体队列的连续神经认知变化。
前瞻性神经学评估(NIHSS 和巴氏指数)、整体认知测试(MMSE 和阿尔茨海默病评估量表认知子量表,ADAS-cog)和执行功能(色迹试验 A 和 B 及言语流畅性),在基线、术后 3 个月和 1 年进行。
在总体队列中,MMSE、ADAS-cog、色迹试验 A 和 B 持续改善至 1 年。根据 STS 评分,研究队列分为低危(<4%,n=81)和中高危(≧4%,n=75)组。中高危组的基线神经和认知表现明显更差。仅在中高危组观察到 1 年后一般神经功能(巴氏指数和 NIHSS>0 患者比例)的轻微改善。在整体认知评估中,两组的 MMSE 和 ADAS-cog 在 1 年内均有改善,但中高危组认知改善的比例更为明显。在色迹试验和言语流畅性方面,仅在低危组观察到直至 1 年的显著和持续改善。
TAVR 与整体认知功能的持续改善相关,1 年内整体队列的注意力和精神运动处理速度也得到改善。然而,执行功能测试的改善仅见于低危组。